Most prostate cancers are initially sensitive to antiandrogen treatment and advanced stage cases of prostate cancer are treated by antiandrogen therapy, for example, by castration, but such cancers later develop resistance (castrate-resistant prostate cancer (CRPC)) although they are still dependent on the AR (androgen receptor) for growth. Here, AR is linked to prostate cancer.